Hemogenyx Pharmaceuticals PLC Approval and Issuance of U.S. Conditioning Patent
February 02 2024 - 1:00AM
RNS Regulatory News
RNS Number : 7658B
Hemogenyx Pharmaceuticals PLC
02 February 2024
2 February 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx Pharmaceuticals" or the "Company")
Approval and Issuance of U.S.
Conditioning Patent
Hemogenyx Pharmaceuticals plc (LSE:
HEMO) is pleased to announce that a patent
application entitled Method of Eliminating
Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) In A
Patient Using Bi-Specific Antibodies has been allowed to be issued as a patent by the United States
Patent and Trademark Office.
Dr
Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals, commented:
"I am excited by the decision of the
United States Patent and Trademark Office to allow this patent
application. This is a significant addition
to the patent protection for CDX which remains one of our key
product candidates for the future. This also
solidifies our Company's position as a leader in the area of
conditioning bone marrow transplants".
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
Peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a pre-clinical stage
biopharmaceutical group developing new medicines and treatments to
treat blood and autoimmune disease and to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and
complementary product candidates, as well as a platform technology
that it uses as an engine for novel product development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCEAKAFELELEFA
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2023 to Apr 2024
